Association study between genetic monoaminergic polymorphisms and OCD response to clomipramine treatment

Imagem de Miniatura
Arquivos
art_MIGUITA_Association_study_between_genetic_monoaminergic_polymorphisms_and_OCD_2011.PDF (1.68 MB)
Citações na Scopus
20
Tipo de produção
article
Data de publicação
2011
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC ARQUIVOS NEURO- PSIQUIATRIA
Autores
MIGUITA, Karen
Citação
ARQUIVOS DE NEURO-PSIQUIATRIA, v.69, n.2B, p.283-287, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
In the present paper, we investigated the 5HTTLPR and STin2 polymorphisms in the promoter region of the serotonin transporter gene (SLC6A4), the G861C polymorphism (rs6296) of the serotonin receptor 1D beta (HTR1B), the T102C (rs6113) and C516T (rs6305) polymorphisms of the serotonin receptor gene subtype 2A (HTR2A), the DAT UTR, DAT intron 8 and DAT intron 14 of the dopamine transporter gene (SLC6A3), the Val-158-Met (rs4680) polymorphism of the COMT and the silent mutation G1287A (rs5569) in the norepinephrine transporter gene (SLC6A2). We genotyped 41 obsessive-compulsive disorder (OCD) outpatients, classified as good-responders (n=27) and poor-responders (n=14) to treatment with clomipramine according to the Yale Brown Obsessive-Compulsive Scale (YBOCS). Patients who achieved a reduction in symptoms of 40% or more in YBOCS after 14 weeks of treatment were considered good-responders. Genotypes and alleles distribution of the investigated polymorphisms were compared between both groups. We did not find association between the studied polymorphisms and clomipramine response in our sample.
Palavras-chave
OCD, clomipramine, serotonin receptor, serotonin transporter, dopamine transporter, norepinephrine transporter
URI
https://observatorio.fm.usp.br/handle/OPI/23409
Referências
  1. American Psychiatric Association, 1994, DIAGN STAT MAN MENT
  2. Greenwood TA, 2003, GENOMICS, V82, P511, DOI 10.1016/S0888-7543(03)00142-3
  3. Guindalini C, 2006, P NATL ACAD SCI USA, V103, P4552, DOI 10.1073/pnas.0504789103
  4. Pigott TA, 1999, J CLIN PSYCHIAT, V60, P101
  5. Heils A, 1996, J NEUROCHEM, V66, P2621
  6. Jonsson EG, 1998, PSYCHIAT RES, V79, P1, DOI 10.1016/S0165-1781(98)00027-4
  7. Daniels JK, 1996, AM J PSYCHIAT, V153, P268
  8. VANDENBERGH DJ, 1992, GENOMICS, V14, P1104, DOI 10.1016/S0888-7543(05)80138-7
  9. Cordeiro Q, 2009, REV BRAS PSIQUIATR, V31, P154, DOI 10.1590/S1516-44462009000200013
  10. de Leon J, 2008, CLIN LAB MED, V28, P599, DOI 10.1016/j.cll.2008.05.003
  11. MacKenzie A, 1999, P NATL ACAD SCI USA, V96, P15251, DOI 10.1073/pnas.96.26.15251
  12. Billett EA, 1997, MOL PSYCHIATR, V2, P403, DOI 10.1038/sj.mp.4000257
  13. ARRANZ M, 1995, LANCET, V346, P281, DOI 10.1016/S0140-6736(95)92168-0
  14. Cavallini MC, 1998, PSYCHIAT RES, V77, P97
  15. Denys D, 2007, J CLIN PSYCHIAT, V68, P747
  16. Di Bella D., 2002, Pharmacogenomics Journal, V2, P176, DOI 10.1038/sj.tpj.6500090
  17. McDougle CJ, 1998, MOL PSYCHIATR, V3, P270, DOI 10.1038/sj.mp.4000391
  18. Mundo E, 2000, AM J PSYCHIAT, V157, P1160, DOI 10.1176/appi.ajp.157.7.1160
  19. Shavitt Roseli G, 2006, Compr Psychiatry, V47, P276, DOI 10.1016/j.comppsych.2005.09.001
  20. Silva MA, 2005, REV MED CHILE, V133, P1392, DOI 10.4067/S0034-98872005001100017
  21. Spina E, 1997, EUR J CLIN PHARMACOL, V51, P395, DOI 10.1007/s002280050220
  22. STAHL SM, 2003, J CLIN PSYCHIAT, V64, P137
  23. WARREN JT, 1993, HUM MOL GENET, V2, P338, DOI 10.1093/hmg/2.3.338

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21
Artigos e Materiais de Revistas Científicas - LIM/23